50 Years of Lassa Fever Research.

Humans Lassa Fever / diagnosis Lassa virus / genetics

Journal

Current topics in microbiology and immunology
ISSN: 0070-217X
Titre abrégé: Curr Top Microbiol Immunol
Pays: Germany
ID NLM: 0110513

Informations de publication

Date de publication:
2023
Historique:
medline: 19 7 2023
pubmed: 28 5 2020
entrez: 28 5 2020
Statut: ppublish

Résumé

Lassa fever was first described as a clinical entity fifty years ago. The causative agent Lassa virus was isolated from these first known cases. This chapter reviews the key publications on Lassa fever research that appeared in the scientific literature at that time and over the ensuing decades.

Identifiants

DOI: 10.1007/82_2020_214 PMID: 32458151
pubmed: 32458151
doi: 10.1007/82_2020_214
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-22

Informations de copyright

© 2020. Springer Nature Switzerland AG.

Références

Abraham J, Corbett KD, Farzan M, Choe H, Harrison SC (2010) Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses. Nat Struct Mol Biol 17:438–444. https://doi.org/10.1038/nsmb.1772
doi: 10.1038/nsmb.1772 pubmed: 20208545
Ahmed R, Salmi A, Butler LD, Chiller JM, Oldstone MB (1984) Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J Exp Med 160:521–540
Ajogbasile FV et al (2020) Real-time metagenomic analysis of undiagnosed fever cases unveils a yellow fever outbreak in Edo State, Nigeria. Sci Rep 10:3180. https://doi.org/10.1038/s41598-020-59880-w
doi: 10.1038/s41598-020-59880-w pubmed: 32081931
Akhuemokhan OC et al (2017) Prevalence of lassa virus disease (LVD) in Nigerian children with fever or fever and convulsions in an endemic area. PLoS Negl Tropical Dis 11:e0005711. https://doi.org/10.1371/journal.pntd.0005711
doi: 10.1371/journal.pntd.0005711
Andersen KG et al (2015) Clinical sequencing uncovers origins and evolution of Lassa virus. Cell 162:738–750. https://doi.org/10.1016/j.cell.2015.07.020
doi: 10.1016/j.cell.2015.07.020 pubmed: 26276630
Arnold RB, Gary GW (1977) A neutralization test survey for Lassa Fever activity in Lassa, Nigeria. Trans R Soc Trop Med Hyg 71:152–154
pubmed: 560072
Auperin DD et al (1988) Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. Virus Res 9:233–248
pubmed: 3354260
Barber GN, Clegg JC, Lloyd G (1990) Expression of the Lassa virus nucleocapsid protein in insect cells infected with a recombinant baculovirus: application to diagnostic assays for Lassa virus infection. J Gen Virol 71(Pt 1):19–28. https://doi.org/10.1099/0022-1317-71-1-19
doi: 10.1099/0022-1317-71-1-19 pubmed: 2406367
Bausch DG et al (2000) Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation. J Clin Microbiol 38:2670–2677
pubmed: 10878062
Bausch DG et al (2001) Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. Vector Borne Zoonotic Dis 1:269–281. https://doi.org/10.1089/15303660160025903
Bausch DG et al (2014) A tribute to Sheik Humarr Khan and all the healthcare workers in West Africa who have sacrificed in the fight against Ebola virus disease: Mae we hush. Antiviral Res 111C:33–35. https://doi.org/10.1016/j.antiviral.2014.09.001
doi: 10.1016/j.antiviral.2014.09.001
Bernasconi V et al (2020) Developing vaccines against epidemic-prone emerging infectious diseases. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 63:65–73. https://doi.org/10.1007/s00103-019-03061-2
doi: 10.1007/s00103-019-03061-2 pubmed: 31776599
Boisen ML et al (2016) Field validation of the ReEBOV antigen rapid test for point-of-care diagnosis of Ebola virus infection. J Infect Dis. https://doi.org/10.1093/infdis/jiw261
doi: 10.1093/infdis/jiw261 pubmed: 27587634
Boisen ML et al (2018) Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. Sci Rep 8:5939. https://doi.org/10.1038/s41598-018-24246-w
doi: 10.1038/s41598-018-24246-w pubmed: 29651117
Bond N, Schieffelin JS, Moses LM, Bennett AJ, Bausch DG (2013) A historical look at the first reported cases of Lassa fever: IgG antibodies 40 years after acute infection. Am J Trop Med Hyg 88:241–244. https://doi.org/10.4269/ajtmh.2012.12-0466
doi: 10.4269/ajtmh.2012.12-0466 pubmed: 23390223
Bowen MD et al (2000) Genetic diversity among Lassa virus strains. J Virol 74:6992–7004. https://doi.org/10.1128/jvi.74.15.6992-7004.2000
doi: 10.1128/jvi.74.15.6992-7004.2000 pubmed: 10888638
Branco LM et al (2008) Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance. Virol J 5:74. https://doi.org/10.1186/1743-422x-5-74
doi: 10.1186/1743-422x-5-74 pubmed: 18538016
Buchmeier MJ, Lewicki HA, Tomori O, Johnson KM (1980) Monoclonal antibodies to lymphocytic choriomeningitis virus react with pathogenic arenaviruses. Nature 288:486–487. https://doi.org/10.1038/288486a0
doi: 10.1038/288486a0 pubmed: 6160402
Buchmeier MJ, Lewicki HA, Tomori O, Oldstone MB (1981) Monoclonal antibodies to lymphocytic choriomeningitis and pichinde viruses: generation, characterization, and cross-reactivity with other arenaviruses. Virology 113:73–85. https://doi.org/10.1016/0042-6822(81)90137-9
doi: 10.1016/0042-6822(81)90137-9 pubmed: 6267791
Buckley SM, Casals J (1970) Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus. Am J Trop Med Hyg 19:680–691
Buckley SM, Casals J, Downs WG (1970) Isolation and antigenic characterization of Lassa virus. Nature 227:174
pubmed: 5428406
Burki T (2017) CEPI: preparing for the worst. The Lancet. Infect Dis 17:265–266. https://doi.org/10.1016/s1473-3099(17)30062-2
doi: 10.1016/s1473-3099(17)30062-2 pubmed: 28244392
Campbell G (2002) Blood diamond: tracing the deadly path of the world’s most precious stones. Westview Press
Cao W et al (1998) Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 282:2079–2081. https://doi.org/10.1126/science.282.5396.2079
doi: 10.1126/science.282.5396.2079 pubmed: 9851928
Carey DE et al (1972) Lassa fever. Epidemiological aspects of the 1970 epidemic, Jos, Nigeria. Trans R Soc Trop Med Hyg 66:402–408
Cashman KA et al (2017a) A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Human Vaccines Immunotherapeutics 13:2902–2911. https://doi.org/10.1080/21645515.2017.1356500
doi: 10.1080/21645515.2017.1356500 pubmed: 29045192
Cashman KA et al (2017b) DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs. Hum Vaccines Immunotherapeutics 13:3010–3019. https://doi.org/10.1080/21645515.2017.1382780
doi: 10.1080/21645515.2017.1382780
Cashman KA. et al (2018) Immune-mediated systemic vasculitis as the proposed cause of sudden-onset sensorineural hearing loss following Lassa virus exposure in cynomolgus macaques. mBio 9. https://doi.org/10.1128/mbio.01896-18
Chu M (2018). In: Barton HA, Whitaker RJ (eds). Ch. 31 Amer Soc Microbiol
Clegg JC, Lloyd G (1983) Structural and cell-associated proteins of Lassa virus. J Gen Virol 64:1127–1136. https://doi.org/10.1099/0022-1317-64-5-1127
doi: 10.1099/0022-1317-64-5-1127 pubmed: 6405010
Clegg JC, Lloyd G (1987) Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Lancet 2:186–188. https://doi.org/10.1016/s0140-6736(87)90767-7
doi: 10.1016/s0140-6736(87)90767-7 pubmed: 2885642
Clegg JC, Barber GN, Chamberlain JF, Oram JD (1986) Expression of Lassa virus nucleocapsid gene fragments in bacteria. Med Microbiol Immunol 175:93–95
pubmed: 3523185
Cross RW et al (2016a) Analytical validation of the ReEBOV antigen rapid test for point-of-care diagnosis of Ebola virus infection. J Infect Dis. https://doi.org/10.1093/infdis/jiw293
doi: 10.1093/infdis/jiw293 pubmed: 27587634
Cross RW et al (2016b) Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antiviral Res 133:218–222. https://doi.org/10.1016/j.antiviral.2016.08.012
doi: 10.1016/j.antiviral.2016.08.012 pubmed: 27531367
Cross RW et al (2019) Antibody therapy for Lassa fever. Curr Opin Virol 37:97–104. https://doi.org/10.1016/j.coviro.2019.07.003
doi: 10.1016/j.coviro.2019.07.003 pubmed: 31401518
Cummins D (1992) Rats, fever and sudden deafness in Sierra Leone. Trop Doct 22:83–84
pubmed: 1604723
Cummins D et al (1989) A plasma inhibitor of platelet aggregation in patients with Lassa fever. Br J Haematol 72:543–548
pubmed: 2775659
Cummins D et al (1990) Acute sensorineural deafness in Lassa fever. JAMA 264:2093–2096
pubmed: 2214077
Demby AH et al (2001) Lassa fever in Guinea: II. Distribution and prevalence of Lassa virus infection in small mammals. Vector Borne Zoonotic Dis 1:283–297. https://doi.org/10.1089/15303660160025912
Eberhardt KA et al (2019) Ribavirin for the treatment of lassa fever: a systematic review and meta-analysis. Int J Infect Dis: IJID: Official Publ Int Soci Infect Dis. https://doi.org/10.1016/j.ijid.2019.07.015
doi: 10.1016/j.ijid.2019.07.015
ECDC (2016) Lassa fever in Nigeria, Benin, Togo, Germany and USA. Eur Centre Dis Prev Control (23 Mar 2016)
Ehichioya DU et al (2011) Current molecular epidemiology of Lassa virus in Nigeria. J Clin Microbiol 49:1157–1161. https://doi.org/10.1128/jcm.01891-10
doi: 10.1128/jcm.01891-10 pubmed: 21191050
Ehichioya DU et al (2019) Phylogeography of Lassa virus in Nigeria. J Virol. https://doi.org/10.1128/jvi.00929-19
doi: 10.1128/jvi.00929-19 pubmed: 31413134
Eichler R, Lenz O, Strecker T, Garten W (2003) Signal peptide of Lassa virus glycoprotein GP-C exhibits an unusual length. FEBS Lett 538:203–206. https://doi.org/10.1016/s0014-5793(03)00160-1
doi: 10.1016/s0014-5793(03)00160-1 pubmed: 12633879
Enria DA, Barrera Oro JG (2002) Junin virus vaccines. Curr Top Microbiol Immunol 263:239–261
Enria DA, Maiztegui JI (1994) Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res 23:23–31
pubmed: 8141590
Enria DA, Briggiler AM, Sanchez Z (2008) Treatment of Argentine hemorrhagic fever. Antiviral Res 78:132–139. https://doi.org/10.1016/j.antiviral.2007.10.010
doi: 10.1016/j.antiviral.2007.10.010 pubmed: 18054395
Enria DA, Ambrosio AM, Briggiler AM, Feuillade MR, Crivelli E (2010) [Candid#1 vaccine against Argentine hemorrhagic fever produced in Argentina. Immunogenicity and safety]. Medicina 70:215–222
Fabiyi A, Tomori O (1975) Use of the complement fixation (CF) test in Lassa fever surveillance. Evidence for persistent CF antibodies. Bull World Health Organ 52, 605–608 (1975)
Fabiyi A, Tomori O, Pinneo P (1979) Lassa fever antibodies in hospital personnel in the Plateau State of Nigeria. Niger Med J 9:23–25
pubmed: 463337
Fichet-Calvet E et al (2007) Fluctuation of abundance and Lassa virus prevalence in Mastomys natalensis in Guinea, West Africa. Vector Borne Zoonotic Dis 7:119–128. https://doi.org/10.1089/vbz.2006.0520
doi: 10.1089/vbz.2006.0520 pubmed: 17627428
Fichet-Calvet E, Lecompte E, Koivogui L, Daffis S, ter Meulen J (2008) Reproductive characteristics of Mastomys natalensis and Lassa virus prevalence in Guinea, West Africa. Vector Borne Zoonotic Dis 8:41–48. https://doi.org/10.1089/vbz.2007.0118
doi: 10.1089/vbz.2007.0118 pubmed: 18237265
Fisher-Hoch SP et al (1985) Safe intensive-care management of a severe case of Lassa fever with simple barrier nursing techniques. Lancet 2:1227–1229
pubmed: 2866301
Fisher-Hoch SP et al (1987) Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever. J Infect Dis 155:465–474. https://doi.org/10.1093/infdis/155.3.465
doi: 10.1093/infdis/155.3.465 pubmed: 3543155
Fisher-Hoch SP et al (1989) Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc Natl Acad Sci U S A 86:317–321. https://doi.org/10.1073/pnas.86.1.317
doi: 10.1073/pnas.86.1.317 pubmed: 2911575
Fisher-Hoch SP et al (1995) Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ 311:857–859
pubmed: 7580496
Frame JD, Baldwin JM, Jr, Gocke DJ, Troup JM (1970) Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg 19:670–676
Frame JD, Casals J, Dennis EA (1979) Lassa virus antibodies in hospital personnel in western Liberia. Trans R Soc Trop Med Hyg 73:219–224. https://doi.org/10.1016/0035-9203(79)90218-9
doi: 10.1016/0035-9203(79)90218-9 pubmed: 382467
Frame JD, Verbrugge GP, Gill RG, Pinneo L (1984) The use of Lassa fever convalescent plasma in Nigeria. Trans R Soc Trop Med Hyg 78:319–324
pubmed: 6464130
Fraser DW, Campbell CC, Monath TP, Goff PA, Gregg MB (1974) Lassa fever in the Eastern Province of Sierra Leone, 1970–1972. I. Epidemiologic studies. Am J Trop Med Hyg 23, 1131–1139. https://doi.org/10.4269/ajtmh.1974.23.1131
Gallaher WR, DiSimone C, Buchmeier MJ (2001) The viral transmembrane superfamily: possible divergence of Arenavirus and Filovirus glycoproteins from a common RNA virus ancestor. BMC Microbiol 1:1
pubmed: 11208257
Garry CE, Garry RF (2019) Proteomics computational analyses suggest that the antennavirus glycoprotein complex includes a class I viral fusion protein (alpha-penetrene) with an Internal zinc-binding domain and a stable signal peptide. Viruses 11. https://doi.org/10.3390/v11080750
Gire SK et al (2014) Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345:1369–1372. https://doi.org/10.1126/science.1259657
doi: 10.1126/science.1259657 pubmed: 25214632
Goba A et al (2016) An outbreak of ebola virus disease in the lassa fever zone. J Infect Dis 214:S110–s121. https://doi.org/10.1093/infdis/jiw239
doi: 10.1093/infdis/jiw239 pubmed: 27402779
Gouglas D, Christodoulou M, Plotkin SA, Hatchett R (2019) CEPI: driving progress towards epidemic preparedness and response. Epidemiol Rev. https://doi.org/10.1093/epirev/mxz012
doi: 10.1093/epirev/mxz012 pubmed: 31673694
Hartnett JN et al (2015) Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever. Future Virol 10:559–584
Hastie KM, Saphire EO (2018) Lassa virus glycoprotein: stopping a moving target. Curr Opin Virol 31:52–58. https://doi.org/10.1016/j.coviro.2018.05.002
doi: 10.1016/j.coviro.2018.05.002 pubmed: 29843991
Hastie KM et al (2011a) Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. Proc Natl Acad Sci U S A 108:19365–19370. https://doi.org/10.1073/pnas.1108515108
doi: 10.1073/pnas.1108515108 pubmed: 22084115
Hastie KM, Kimberlin CR, Zandonatti MA, MacRae IJ, Saphire EO (2011b) Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3′ to 5′ exonuclease activity essential for immune suppression. Proc Natl Acad Sci U S A 108:2396–2401. https://doi.org/10.1073/pnas.1016404108
doi: 10.1073/pnas.1016404108 pubmed: 21262835
Hastie KM, Bale S, Kimberlin CR, Saphire EO (2012a) Hiding the evidence: two strategies for innate immune evasion by hemorrhagic fever viruses. Curr Opin Virol 2:151–156. https://doi.org/10.1016/j.coviro.2012.01.003
doi: 10.1016/j.coviro.2012.01.003 pubmed: 22482712
Hastie KM, King LB, Zandonatti MA, Saphire EO (2012b) Structural basis for the dsRNA specificity of the Lassa virus NP exonuclease. PLoS ONE 7:e44211. https://doi.org/10.1371/journal.pone.0044211
doi: 10.1371/journal.pone.0044211 pubmed: 22937163
Hastie KM et al (2017) Structural basis for antibody-mediated neutralization of Lassa virus. Science 356:923–928. https://doi.org/10.1126/science.aam7260
doi: 10.1126/science.aam7260 pubmed: 28572385
Hastie KM et al (2019) Convergent structures illuminate features for germline antibody binding and pan-lassa virus neutralization. Cell 178:1004–1015.e1014. https://doi.org/10.1016/j.cell.2019.07.020
doi: 10.1016/j.cell.2019.07.020 pubmed: 31398326
Henderson BE, Gary GW, Jr, Kissling RE, Frame JD, Carey DE (1972) Lassa fever. Virological and serological studies. Trans R Soc Trop Med Hyg 66:409–416
Jahrling PB et al (2014) The NIAID integrated research facility at Frederick, Maryland: a unique international resource to facilitate medical countermeasure development for BSL-4 pathogens. Pathog Dis 71:213–219. https://doi.org/10.1111/2049-632x.12171
doi: 10.1111/2049-632x.12171 pubmed: 24687975
Jiang J et al (2019) Immunogenicity of a protective intradermal DNA vaccine against Lassa virus in cynomolgus macaques. Human Vaccines & Immunotherapeutics 15:2066–2074. https://doi.org/10.1080/21645515.2019.1616499
doi: 10.1080/21645515.2019.1616499
Johnson KM, Monath TP (1990) Imported Lassa fever–reexamining the algorithms. N Engl J Med 323:1139–1141
pubmed: 2215584
Johnson KM et al (1987) Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 155:456–464. https://doi.org/10.1093/infdis/155.3.456
doi: 10.1093/infdis/155.3.456 pubmed: 3805773
Kafetzopoulou LE et al (2019) Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak. Science 363:74–77. https://doi.org/10.1126/science.aau9343
doi: 10.1126/science.aau9343 pubmed: 30606844
Keenlyside RA et al (1983) Case-control study of Mastomys natalensis and humans in Lassa virus-infected households in Sierra Leone. Am J Trop Med Hyg 32:829–837
pubmed: 6881432
Kerneis S et al (2009) Prevalence and risk factors of Lassa seropositivity in inhabitants of the forest region of Guinea: a cross-sectional study. PLoS Negl Tropical Dis 3:e548. https://doi.org/10.1371/journal.pntd.0000548
doi: 10.1371/journal.pntd.0000548
Khan SH et al (2008) New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res 78:103–115. https://doi.org/10.1016/j.antiviral.2007.11.003
doi: 10.1016/j.antiviral.2007.11.003 pubmed: 18241935
Kiley MP, Lange JV, Johnson KM (1979) Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus. Lancet 2:738. https://doi.org/10.1016/s0140-6736(79)90659-7
doi: 10.1016/s0140-6736(79)90659-7 pubmed: 90819
Klavinskis LS, Oldstone MB (1989) Lymphocytic choriomeningitis virus selectively alters differentiated but not housekeeping functions: block in expression of growth hormone gene is at the level of transcriptional initiation. Virology 168:232–235. https://doi.org/10.1016/0042-6822(89)90262-6
doi: 10.1016/0042-6822(89)90262-6 pubmed: 2916325
Kunz S, Sevilla N, McGavern DB, Campbell KP, Oldstone MB (2001) Molecular analysis of the interaction of LCMV with its cellular receptor [alpha]-dystroglycan. J Cell Biol 155:301–310. https://doi.org/10.1083/jcb.200104103
doi: 10.1083/jcb.200104103 pubmed: 11604425
Kunz S, Campbell KP, Oldstone MB (2003) Alpha-dystroglycan can mediate arenavirus infection in the absence of beta-dystroglycan. Virology 316:213–220. https://doi.org/10.1016/j.virol.2003.07.002
doi: 10.1016/j.virol.2003.07.002 pubmed: 14644604
Kunz S, Calder L, Oldstone MB (2004a) Electron microscopy of an alpha-dystroglycan fragment containing receptor sites for lymphocytic choriomeningitis virus and laminin, and use of the receptoid body as a reagent to neutralize virus. Virology 325:207–215. https://doi.org/10.1016/j.virol.2004.04.044
doi: 10.1016/j.virol.2004.04.044 pubmed: 15246261
Kunz S, Sevilla N, Rojek JM, Oldstone MB (2004b) Use of alternative receptors different than alpha-dystroglycan by selected isolates of lymphocytic choriomeningitis virus. Virology 325:432–445. https://doi.org/10.1016/j.virol.2004.05.009
doi: 10.1016/j.virol.2004.05.009 pubmed: 15246281
Kunz S, Rojek JM, Perez M, Spiropoulou CF, Oldstone MB (2005) Characterization of the interaction of lassa fever virus with its cellular receptor alpha-dystroglycan. J Virol 79:5979–5987. https://doi.org/10.1128/jvi.79.10.5979-5987.2005
doi: 10.1128/jvi.79.10.5979-5987.2005 pubmed: 15857984
Lange JV et al (1985) Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in Mopeia virus-infected monkeys. Am J Trop Med Hyg 34:999–1007
pubmed: 4037187
Lecompte E et al (2006) Mastomys natalensis and Lassa fever, West Africa. Emerg Infect Dis 12:1971–1974. https://doi.org/10.3201/eid1212.060812
doi: 10.3201/eid1212.060812 pubmed: 17326956
Lee KJ, Novella IS, Teng MN, Oldstone MB, de La Torre JC (2000) NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J Virol 74:3470–3477. https://doi.org/10.1128/jvi.74.8.3470-3477.2000
doi: 10.1128/jvi.74.8.3470-3477.2000 pubmed: 10729120
Leifer E, Gocke DJ, Bourne H (1970) Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. Am J Trop Med Hyg 19:677–679
Lloyd G, Barber GN, Clegg JC, Kelly P (1989) Identification of Lassa fever virus infection with recombinant nucleocapsid protein antigen. Lancet 2:1222. https://doi.org/10.1016/s0140-6736(89)91833-3
doi: 10.1016/s0140-6736(89)91833-3 pubmed: 2572935
Lukashevich IS (1985) Lassa virus lethality for inbred mice. Ann Soc Belg Med Trop 65:207–209
pubmed: 4037900
Lukashevich IS, Vasiuchkov AD, Mar’iankova RF, Votiakov VI (1982) [Factors affecting plaque formation by Lassa virus in Vero cells]. Vopr Virusol, 57–61
Lukashevich IS, Maryankova RF, Fidarov FM (1983) Reproduction of Lassa virus in different cell cultures. Acta Virol 27:282–285
pubmed: 6138991
Lukashevich LS, Clegg JC, Sidibe K (1993) Lassa virus activity in Guinea: distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen. J Med Virol 40:210–217
pubmed: 8355019
Lukashevich IS et al (1997) The Lassa fever virus L gene: nucleotide sequence, comparison, and precipitation of a predicted 250 kDa protein with monospecific antiserum. J Gen Virol 78(Pt 3):547–551. https://doi.org/10.1099/0022-1317-78-3-547
doi: 10.1099/0022-1317-78-3-547 pubmed: 9049403
Lukashevich IS et al (1999) Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-alpha gene expression. J Med Virol 59:552–560
pubmed: 10534741
Lukashevich IS et al (2008) Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 26:5246–5254. https://doi.org/10.1016/j.vaccine.2008.07.057
doi: 10.1016/j.vaccine.2008.07.057 pubmed: 18692539
Lunkenheimer K, Hufert FT, Schmitz H (1990) Detection of Lassa virus RNA in specimens from patients with Lassa fever by using the polymerase chain reaction. J Clin Microbiol 28:2689–2692
pubmed: 2279999
Madu IG et al (2018) A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog 14:e1007439. https://doi.org/10.1371/journal.ppat.1007439
doi: 10.1371/journal.ppat.1007439 pubmed: 30576397
Mahmutovic S et al (2015) Molecular basis for antibody-mediated neutralization of new world hemorrhagic fever mammarenaviruses. Cell Host Microbe 18:705–713. https://doi.org/10.1016/j.chom.2015.11.005
doi: 10.1016/j.chom.2015.11.005 pubmed: 26651946
Manning JT, Forrester N, Paessler S (2015) Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage. Front Microbiol 6:1037. https://doi.org/10.3389/fmicb.2015.01037
doi: 10.3389/fmicb.2015.01037 pubmed: 26483768
Matranga CB et al (2014) Enhanced methods for unbiased deep sequencing of Lassa and Ebola RNA viruses from clinical and biological samples. Genome Biol 15:519. https://doi.org/10.1186/preaccept-1698056557139770
doi: 10.1186/preaccept-1698056557139770 pubmed: 25403361
McCormick JB (1986) Clinical, epidemiologic, and therapeutic aspects of Lassa fever. Med Microbiol Immunol (Berl) 175:153–155
pubmed: 3724661
McCormick JB et al (1986) Lassa fever. Effective therapy with ribavirin. N Engl J Med 314:20–26
McCormick JB, Fisher-Hoch S (1996) Level 4 Virus Hunters of the CDC (379). Turner Publications
McCormick JB et al (1987a) A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis 155:445–455
pubmed: 3805772
McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES (1987b) A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 155:437–444. https://doi.org/10.1093/infdis/155.3.437
doi: 10.1093/infdis/155.3.437 pubmed: 3805771
McCormick JB, Mitchell SW, Kiley MP, Ruo S, Fisher-Hoch SP (1992) Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J Med Virol 37:1–7
pubmed: 1619397
Mehand MS, Al-Shorbaji F, Millett P, Murgue B (2018) The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. Antiviral Res 159:63–67. https://doi.org/10.1016/j.antiviral.2018.09.009
doi: 10.1016/j.antiviral.2018.09.009 pubmed: 30261226
Mire CE et al (2017) Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat Med 23:1146–1149. https://doi.org/10.1038/nm.4396
doi: 10.1038/nm.4396 pubmed: 28869611
Monath TP (2019) A short history of Lassa fever: the first 10–15 years after discovery. Curr Opin Virol 37:77–83. https://doi.org/10.1016/j.coviro.2019.06.005
doi: 10.1016/j.coviro.2019.06.005 pubmed: 31323506
Monath TP et al (1973) A hospital epidemic of Lassa fever in Zorzor, Liberia, March–April 1972. Am J Trop Med Hyg 22:773–779. https://doi.org/10.4269/ajtmh.1973.22.773
doi: 10.4269/ajtmh.1973.22.773 pubmed: 4745236
Monath TP, Maher M, Casals J, Kissling RE, Cacciapuoti A (1974a) Lassa fever in the Eastern Province of Sierra Leone, 1970–1972. II. Clinical observations and virological studies on selected hospital cases. Am J Trop Med Hyg 23:1140–1149. https://doi.org/10.4269/ajtmh.1974.23.1140
Monath TP, Newhouse VF, Kemp GE, Setzer HW, Cacciapuoti A (1974b) Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 185:263–265. https://doi.org/10.1126/science.185.4147.263
doi: 10.1126/science.185.4147.263 pubmed: 4833828
Morrison HG et al (1989) Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus. Virology 171:179–188. https://doi.org/10.1016/0042-6822(89)90525-4
doi: 10.1016/0042-6822(89)90525-4 pubmed: 2741340
Okogbenin S et al (2019) Retrospective cohort study of lassa fever in pregnancy, Southern Nigeria. Emerg Infect Dis 25, https://doi.org/10.3201/eid2508.181299
Okokhere P et al (2018) Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. Lancet Infect Dis 18:684–695. https://doi.org/10.1016/s1473-3099(18)30121-x
doi: 10.1016/s1473-3099(18)30121-x pubmed: 29523497
Olayemi A et al (2016a) Arenavirus diversity and phylogeography of Mastomys natalensis rodents, Nigeria. Emerg Infect Dis 22:694–697. https://doi.org/10.3201/eid2204.150155
doi: 10.3201/eid2204.150155 pubmed: 26982388
Olayemi A et al (2016b) New hosts of the Lassa virus. Sci Rep 6:25280. https://doi.org/10.1038/srep25280
doi: 10.1038/srep25280 pubmed: 27140942
Oldstone MB, Dixon FJ (1970) Tissue injury in lymphocytic choriomeningitis viral infection: virus-induced immunologically specific release of a cytotoxic factor from immune lymphoid cells. Virology 42:805–813
pubmed: 4992354
Oldstone MB, Dixon FJ (1972) Disease accompanying in utero viral infection. The role of maternal antibody in tissue injury after transplacental infection with lymphocytic choriomeningitis virus. J Exp Med 135:827–838. https://doi.org/10.1084/jem.135.4.827
Oldstone MB, Dixon FJ, Mitchell GF, McDevitt HO (1973) Histocompatibility-linked genetic control of disease susceptibility. Murine lymphocytic choriomeningitis virus infection. J Exp Med 137:1201–1212. https://doi.org/10.1084/jem.137.5.1201
Oldstone MB, Buchmeier MJ, Doyle MV, Tishon A (1980) Virus-induced immune complex disease: specific anti-viral antibody and C1q binding material in the circulation during persistent lymphocytic choriomeningitis virus infection. J Immunol 124:831–838
pubmed: 6444319
Oldstone MB et al (1985) Virus and immune responses: lymphocytic choriomeningitis virus as a prototype model of viral pathogenesis. Br Med Bull 41:70–74. https://doi.org/10.1093/oxfordjournals.bmb.a072029
doi: 10.1093/oxfordjournals.bmb.a072029 pubmed: 3882190
Oldstone MB et al (1990) Cytotoxic T lymphocytes do not control lymphocytic choriomeningitis virus infection of BB diabetes-prone rats. J Gen Virol 71(Pt 4):785–791. https://doi.org/10.1099/0022-1317-71-4-785
doi: 10.1099/0022-1317-71-4-785 pubmed: 2324708
Oloniniyi OK et al (2018) Genetic characterization of Lassa virus strains isolated from 2012 to 2016 in southeastern Nigeria. PLoS Negl Tropical Dis 12:e0006971. https://doi.org/10.1371/journal.pntd.0006971
doi: 10.1371/journal.pntd.0006971
Omilabu SA et al (2005) Lassa fever, Nigeria, 2003 and 2004. Emerg Infect Dis 11:1642–1644. https://doi.org/10.3201/eid1110.041343
doi: 10.3201/eid1110.041343 pubmed: 16355508
Peng R et al (2020) Structural insight into arenavirus replication machinery. Nature 579:615–619. https://doi.org/10.1038/s41586-020-2114-2
doi: 10.1038/s41586-020-2114-2 pubmed: 32214249
Petkevich AS, Sabynin VM, Lukashevich IS, Galegov GA, Votiakov VI (1981) [Effect of ribovirin (virazole) on arenavirus reproduction in cell cultures]. Vopr Virusol 244–245
Pinneo L, Pinneo R (1971) Mystery virus from Lassa. Am J Nurs 71:1352–1355
pubmed: 4996954
Price ME, Fisher-Hoch SP, Craven RB, McCormick JB (1988) A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. BMJ 297:584–587
pubmed: 3139220
Riviere Y, Ahmed R, Southern PJ, Buchmeier MJ, Oldstone MB (1985) Genetic mapping of lymphocytic choriomeningitis virus pathogenicity: virulence in guinea pigs is associated with the L RNA segment. J Virol 55:704–709
pubmed: 4020963
Riviere Y, Southern PJ, Ahmed R, Oldstone MB (1986) Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus. V. Recognition is restricted to gene products encoded by the viral S RNA segment. J Immunol 136:304–307
Roberts PJ et al (1989) Plasma from patients with severe Lassa fever profoundly modulates f-met-leu-phe induced superoxide generation in neutrophils. Br J Haematol 73:152–157
pubmed: 2554951
Robinson JE et al (2016) Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat Commun 7:11544. https://doi.org/10.1038/ncomms11544
doi: 10.1038/ncomms11544 pubmed: 27161536
Rose JR (1956) A new clinical entity? Lancet 2:197
Rybak LP (1990) Deafness associated with Lassa fever. Jama 264:2119
pubmed: 2214082
Ryschon TW (2014) Ebola control measures and inadequate responses. Lancet 384:1181–1182. https://doi.org/10.1016/s0140-6736(14)61346-5
doi: 10.1016/s0140-6736(14)61346-5 pubmed: 25217114
Sabeti PC et al (2006) Positive natural selection in the human lineage. Science 312:1614–1620. https://doi.org/10.1126/science.1124309
doi: 10.1126/science.1124309 pubmed: 16778047
Sabeti PC et al (2007) Genome-wide detection and characterization of positive selection in human populations. Nature 449:913–918. https://doi.org/10.1038/nature06250
doi: 10.1038/nature06250 pubmed: 17943131
Safronetz D et al (2013) Geographic distribution and genetic characterization of Lassa virus in sub-Saharan Mali. PLoS Neg Trop Dis 7:e2582. https://doi.org/10.1371/journal.pntd.0002582
doi: 10.1371/journal.pntd.0002582
Salvato M, Borrow P, Shimomaye E, Oldstone MB (1991) Molecular basis of viral persistence: a single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with suppression of the antiviral cytotoxic T-lymphocyte response and establishment of persistence. J Virol 65:1863–1869
pubmed: 1840619
Schieffelin JS et al (2014) Clinical illness and outcomes in patients with Ebola in sierra leone. N Engl J Med 371:2092–2100. https://doi.org/10.1056/NEJMoa1411680
doi: 10.1056/NEJMoa1411680 pubmed: 25353969
Schmitz H, Emmerich P, ter Meulen J (1996) Imported tropical virus infections in Germany. Arch Virol Suppl 11:67–74
pubmed: 8800807
Schmitz H et al (2002) Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect 4:43–50
pubmed: 11825774
Shaffer JG et al (2014) Lassa fever in post-conflict sierra leone. PLoS Negl Tropical Dis 8:e2748. https://doi.org/10.1371/journal.pntd.0002748
doi: 10.1371/journal.pntd.0002748
Siddle KJ et al (2018a) Genomic analysis of Lassa virus, 2018 Nigeria. NEJM accepted
Siddle KJ et al (2018b) Genomic analysis of lassa virus during an increase in cases in Nigeria in 2018. N Engl J Med 379:1745–1753. https://doi.org/10.1056/NEJMoa1804498
doi: 10.1056/NEJMoa1804498 pubmed: 30332564
Smelt SC et al (2001) Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor alpha-dystroglycan correlate with viral tropism and disease kinetics. J Virol 75:448–457. https://doi.org/10.1128/jvi.75.1.448-457.2001
doi: 10.1128/jvi.75.1.448-457.2001 pubmed: 11119613
Smith EA, Fabiyi A, Kuteyi OE, Tomori O (1979) Epidemiological aspect of the 1976 Pankshin Lassa fever outbreak. Niger Med J 9:20–22
pubmed: 463336
Southern PJ et al (1987) Molecular characterization of the genomic S RNA segment from lymphocytic choriomeningitis virus. Virology 157:145–155. https://doi.org/10.1016/0042-6822(87)90323-0
doi: 10.1016/0042-6822(87)90323-0 pubmed: 3824905
Speir RW, Wood O, Liebhaber H, Buckley SM (1970) Lassa fever, a new virus disease of man from West Africa. IV. Electron microscopy of Vero cell cultures infected with Lassa virus. Am J Trop Med Hyg 19:692–694. https://doi.org/10.4269/ajtmh.1970.19.692
Spiropoulou CF, Kunz S, Rollin PE, Campbell KP, Oldstone MB (2002) New World arenavirus clade C, but not clade A and B viruses, utilizes alpha-dystroglycan as its major receptor. J Virol 76:5140–5146. https://doi.org/10.1128/jvi.76.10.5140-5146.2002
doi: 10.1128/jvi.76.10.5140-5146.2002 pubmed: 11967329
Stephen EL, Jahrling PB (1979) Experimental Lassa fever virus infection successfully treated with ribavirin. Lancet 1:268–269
pubmed: 84919
Strecker T et al (2003) Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles [corrected]. J Virol 77:10700–10705. https://doi.org/10.1128/jvi.77.19.10700-10705.2003
doi: 10.1128/jvi.77.19.10700-10705.2003 pubmed: 12970458
Sullivan BM et al (2011) Point mutation in the glycoprotein of lymphocytic choriomeningitis virus is necessary for receptor binding, dendritic cell infection, and long-term persistence. Proc Natl Acad Sci U S A 108:2969–2974. https://doi.org/10.1073/pnas.1019304108
doi: 10.1073/pnas.1019304108 pubmed: 21270335
Sullivan BM et al (2020) High crossreactivity of human T cell responses between Lassa virus lineages. PLoS Pathog 16:e1008352. https://doi.org/10.1371/journal.ppat.1008352
doi: 10.1371/journal.ppat.1008352 pubmed: 32142546
Teng MN, Borrow P, Oldstone MB, de la Torre JC (1996) A single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with the ability to cause growth hormone deficiency syndrome. J Virol 70:8438–8443
pubmed: 8970965
Tishon A, Southern PJ, Oldstone MB (1988) Virus-lymphocyte interactions. II. Expression of viral sequences during the course of persistent lymphocytic choriomeningitis virus infection and their localization to the L3T4 lymphocyte subset. J Immunol 140:1280–1284
Tishon A, Eddleston M, de la Torre JC, Oldstone MB (1993) Cytotoxic T lymphocytes cleanse viral gene products from individually infected neurons and lymphocytes in mice persistently infected with lymphocytic choriomeningitis virus. Virology 197:463–467. https://doi.org/10.1006/viro.1993.1613
doi: 10.1006/viro.1993.1613 pubmed: 8212586
Tomori O, Fabiyi A (1979) Lassa fever virus: properties and characteristics. Niger Med J 9:17–19
pubmed: 111436
Tomori O, Johnson KM, Kiley MP, Elliott LH (1987) Standardization of a plaque assay for Lassa virus. J Med Virol 22:77–89
pubmed: 3585290
Tomori O, Fabiyi A, Sorungbe A, Smith A, McCormick JB (1988) Viral hemorrhagic fever antibodies in Nigerian populations. Am J Trop Med Hyg 38:407–410. https://doi.org/10.4269/ajtmh.1988.38.407
doi: 10.4269/ajtmh.1988.38.407 pubmed: 3128130
Tomori O et al (1999) Serologic survey among hospital and health center workers during the Ebola hemorrhagic fever outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179(Suppl 1):S98–101. https://doi.org/10.1086/514307
doi: 10.1086/514307 pubmed: 9988171
Trappier SG et al (1993) Evaluation of the polymerase chain reaction for diagnosis of Lassa virus infection. Am J Trop Med Hyg 49:214–221
pubmed: 8357084
Troup JM, White HA, Fom AL, Carey DE (1970) An outbreak of Lassa fever on the Jos plateau, Nigeria, in January-February 1970. A preliminary report. Am J Trop Med Hyg 19:695–696
Valsamakis V et al (1986) Dissecting the molecular anatomy of persistent infection with lymphocytic choriomeningitis virus. Med Microbiol Immunol 175:97–99
pubmed: 3724670
Vieth S, Torda AE, Asper M, Schmitz H, Gunther S (2004) Sequence analysis of L RNA of Lassa virus. Virology 318:153–168. https://doi.org/10.1016/j.virol.2003.09.009
doi: 10.1016/j.virol.2003.09.009 pubmed: 14972544
Walker DH et al (1982a) Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus. J Infect Dis 146:360–368
pubmed: 6286795
Walker DH et al (1982b) Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol 107:349–356
pubmed: 7081389
Watts GM (2013) Lily Lyman Pinneo. The Lancet 380:1552
Webb PA et al (1986) Lassa fever in children in Sierra Leone, West Africa. Trans R Soc Trop Med Hyg 80:577–582
pubmed: 3810792
Welsh RM, Oldstone MB (1977) Inhibition of immunologic injury of cultured cells infected with lymphocytic choriomeningitis virus: role of defective interfering virus in regulating viral antigenic expression. J Exp Med 145:1449–1468. https://doi.org/10.1084/jem.145.6.1449
doi: 10.1084/jem.145.6.1449 pubmed: 301173
Welsh RM, Lampert PW, Oldstone MB (1977) Prevention of virus-induced cerebellar diseases by defective-interfering lymphocytic choriomeningitis virus. J Infect Dis 136:391–399. https://doi.org/10.1093/infdis/136.3.391
doi: 10.1093/infdis/136.3.391 pubmed: 903677
White HA (1972) Lassa fever. A study of 23 hospital cases. Trans R Soc Trop Med Hyg 66:390–401
Whitmer SLM et al (2018) New Lineage of Lassa Virus, Togo, 2016. Emerg Infect Dis 24:599–602. https://doi.org/10.3201/eid2403.171905
doi: 10.3201/eid2403.171905 pubmed: 29460758
Whitton JL, Southern PJ, Oldstone MB (1988) Analyses of the cytotoxic T lymphocyte responses to glycoprotein and nucleoprotein components of lymphocytic choriomeningitis virus. Virology 162:321–327. https://doi.org/10.1016/0042-6822(88)90471-0
doi: 10.1016/0042-6822(88)90471-0 pubmed: 3257596
WHO (2017) Lassa Fever—Benin, Togo and Burkina Faso. Disease outbreak news, 10 Mar 2017
Wiley MR et al (2019) Lassa virus circulating in Liberia: a retrospective genomic characterisation. The Lancet. Infect Dis. https://doi.org/10.1016/s1473-3099(19)30486-4
doi: 10.1016/s1473-3099(19)30486-4 pubmed: 31588039
Wright P (2004) Aniru Conteh. Lancet 363:1831
pubmed: 15190887
Wulff H, Johnson KM (1979) Immunoglobulin M and G responses measured by immunofluorescence in patients with Lassa or Marburg virus infections. Bull World Health Organ 57:631–635
pubmed: 118812
Yadouleton A et al (2019) Lassa virus in Pygmy Mice, Benin, West Africa, 2016–2017. Emerg Infect Dis 25 https://doi.org/10.3201/eid2510.180523
York J, Nunberg JH (2006) Role of the stable signal peptide of Junin arenavirus envelope glycoprotein in pH-dependent membrane fusion. J Virol 80:7775–7780. https://doi.org/10.1128/jvi.00642-06
doi: 10.1128/jvi.00642-06 pubmed: 16840359
York J, Nunberg JH (2007) A novel zinc-binding domain is essential for formation of the functional Junin virus envelope glycoprotein complex. J Virol 81:13385–13391. https://doi.org/10.1128/jvi.01785-07
doi: 10.1128/jvi.01785-07 pubmed: 17928348
York J, Nunberg JH (2018) A cell-cell fusion assay to assess arenavirus envelope glycoprotein membrane-fusion activity. Methods Mol Biol 1604:157–167. https://doi.org/10.1007/978-1-4939-6981-4_10
doi: 10.1007/978-1-4939-6981-4_10 pubmed: 28986831
York J, Romanowski V, Lu M, Nunberg JH (2004) The signal peptide of the Junin arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1–G2 complex. J Virol 78:10783–10792. https://doi.org/10.1128/jvi.78.19.10783-10792.2004
doi: 10.1128/jvi.78.19.10783-10792.2004 pubmed: 15367645
York J, Dai D, Amberg SM, Nunberg JH (2008) pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors. J Virol 82:10932–10939. https://doi.org/10.1128/jvi.01140-08
doi: 10.1128/jvi.01140-08 pubmed: 18768973
York J et al (2010) An antibody directed against the fusion peptide of Junin virus envelope glycoprotein GPC inhibits pH-induced membrane fusion. J Virol 84:6119–6129. https://doi.org/10.1128/jvi.02700-09
doi: 10.1128/jvi.02700-09 pubmed: 20392854

Auteurs

Robert F Garry (RF)

Department of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA, 70118, USA. rfgarry@tulane.edu.
Zalgen Labs, LLC, 20271 Goldenrod Lane, Suite 2083, Germantown, MD, 20876, USA. rfgarry@tulane.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › 50 Years of Lassa Fever Research.
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Fièvres hémorragiques virales › Fièvre de Lassa › 50 Years of Lassa Fever Research.
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN de polarité négative › Arenaviridae › Arenavirus › Arénavirus de l'Ancien Monde › Virus de Lassa › 50 Years of Lassa Fever Research.